2013-08-22 14:16:44 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Innate Pharma SA (IPH) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Innate Pharma SA (IPH). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Innate Pharma SA investor.
Report Summary: Innate Pharma SA is a below average quality company with a positive outlook. Innate Pharma SA has strong business growth and is run by mediocre management. The trend in Innate Pharma SA fair value exchange rate against its closest rated-competitor, BioAlliance Pharma SA, has been appreciating over the past 2 weeks. When compared to its closest competitor, Innate Pharma SA shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its
three components - business, management and price, performing an in-depth analysis of Innate Pharma SA for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.